GROUPE FRANCOPHONE DES MYELODYSPLASIES

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Erlotinib in Higher Risk Myelodysplastic Syndrome

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-03-12
Last Posted Date
2016-11-08
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
30
Registration Number
NCT01085838
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

CHRU Huriez, Lille, France

🇫🇷

Hôpital Avicenne, Bobigny, France

and more 11 locations

Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-02-05
Last Posted Date
2014-03-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
76
Registration Number
NCT01063257
Locations
🇫🇷

Institut Paoli-Calmettes, Marseille, France

🇫🇷

Hôpital Avicenne, Bobigny, France

🇫🇷

Hôpital Saint-Louis, Paris, France

and more 2 locations

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

First Posted Date
2009-11-18
Last Posted Date
2014-03-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
98
Registration Number
NCT01015352
Locations
🇫🇷

Hôpital Brabois, Nancy, France

🇫🇷

Hôpital Avignon, Avignon, France

🇫🇷

Hôpital Archet1, Nice, France

and more 26 locations

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

First Posted Date
2009-04-22
Last Posted Date
2015-04-24
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
85
Registration Number
NCT00885508
Locations
🇫🇷

Centre henri Mondor, Creteil, France

🇫🇷

CH Angers, Angers, France

🇫🇷

hopital Victor Dupouy, Argenteuil, France

and more 22 locations

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-10-21
Last Posted Date
2014-03-20
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
52
Registration Number
NCT00776503
Locations
🇫🇷

CH René Dubos, Cergy-pontoise, France

🇫🇷

Hematology Dpt, Hôpital Sud Francilien, Corbeil-essonnes, France

🇫🇷

Hôpital de la Durance, Avignon, France

and more 11 locations

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Phase 2
Completed
Conditions
First Posted Date
2007-04-04
Last Posted Date
2007-04-04
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
112
Registration Number
NCT00455910
Locations
🇫🇷

CHU Albert Michallon, Grenoble, France

🇫🇷

CH d'Avignon, Avignon, France

🇫🇷

Hopital Avicenne, Bobigny, France

and more 17 locations

A Phase II Study of Maintenance With Azacitidine in MDS Patients

First Posted Date
2007-03-12
Last Posted Date
2012-01-19
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
39
Registration Number
NCT00446303
Locations
🇫🇷

CHU de Caen, Caen, France

🇫🇷

CHU d'Amiens, Amiens, France

🇫🇷

Hopital d'Instruction des Armées Percy, Clamart, France

and more 22 locations

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Phase 2
Conditions
First Posted Date
2007-03-06
Last Posted Date
2007-05-17
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
99
Registration Number
NCT00443339
Locations
🇫🇷

CHU d'Avignon, Avignon, France

🇫🇷

Hopital Percy, Clamart, France

🇫🇷

CHU de Caen, Caen, France

and more 24 locations

Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

First Posted Date
2007-02-21
Last Posted Date
2009-11-18
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
99
Registration Number
NCT00437450
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

CHU d'Avignon, Avignon, France

🇫🇷

CHU de Caen, Caen, France

and more 21 locations

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Phase 2
Conditions
First Posted Date
2007-01-18
Last Posted Date
2007-03-12
Lead Sponsor
Groupe Francophone des Myelodysplasies
Target Recruit Count
49
Registration Number
NCT00424229
Locations
🇫🇷

Hopital Archet, Nice, France

🇫🇷

CHRU Hurriez, Lille, France

🇫🇷

CHU Angers, Angers, France

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath